Hainan Haiyao (SHE:000566) subsidiary Chongqing Tiandi Pharmaceutical received approval from China's drug administrator for its chemical active pharmaceutical ingredient application of vonoprazan fumarate.
Vonoprazan fumarate is a potassium ion competitive acid blocker, according to a Thursday filing with the Shenzhen bourse.
Shares of the drugmaker closed 5% higher Thursday.